Anzeige
Mehr »
Login
Mittwoch, 25.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

AFX News-Archiv vom 08.12.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
08.12.Japan GDP Data Due On Monday303BEIJING (dpa-AFX) - Japan will on Monday release Q3 figures for gross domestic product, highlighting a light day for Asia-Pacific economic activity. GDP is seen steady from the three months...
► Artikel lesen
08.12.Sanofi-Aventis Announces Positive Results For Rilzabrutinib In Phase 3 ITP Study797PARIS (dpa-AFX) - Sanofi-Aventis Groupe announced positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP),...
► Artikel lesen
08.12.Beam Therapeutics Announces Positive Data From Phase 1/2 Trial Of BEAM-101 In Sickle Cell Disease519WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with...
► Artikel lesen
08.12.Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma731WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment to enhance complete response rate...
► Artikel lesen
08.12.AbbVie: Epcoritamab Combo Shows High Response Rates In R/R Follicular Lymphoma Trial593WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging...
► Artikel lesen
08.12.REGN: Poze-Cemdi Combo In Phase 3 Result Shows Superior Hemolysis Control In PNH Vs. Ravulizumab601WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab...
► Artikel lesen